From CDMO exit to CDMO+

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Tim Scott, President and CEO, AustinPx.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Tim, covering: 

• The founding story of Pharmatek, and how client centricity and ‘training the hell out of the team’ contributed to the growth
• How the niche of being a spray drying expert led to a sale of Pharmatek to Catalent... and why he didn’t last very long post-acquisition
• The disruptive technology and team that got Tim so excited... he came back to the ‘CDMO+’ world in Austin
• Building traction for a game-changing technology for poorly soluble compounds to get it into 100 molecules and commercial products

Tim brings more than twenty years of pharmaceutical contract development and manufacturing organization (CDMO) leadership experience. Previously, Mr. Scott was co-founder and president of Pharmatek Laboratories, a CDMO where he led the growth and ultimate sale of the company to Catalent. He currently serves on the boards of multiple organizations, including Avelas Biosciences, DTx Pharma, CONNECT, BIOCOM, and the University of California, San Diego’s Dean’s Advisory Council for the Division of Biological Sciences. He previously served on the board of Zacharon Pharmaceuticals (sold to BioMarin in 2014). At UC San Diego, Tim has founded or supported multiple biotech spinouts including Zacharon, TEGA therapeutics, LipoNexus, Knoubis Bio, Nerio and Augment Biosciences. Mr Scott earned his BA in Biochemistry from UC San Diego and his JD from the University of San Diego. He is a member of the California Bar.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.